Peptide Therapeutics Market is Expected to Reach US$ 46.6 Billion by 2024

Peptides are basically the combination/synthesis of two or more amino acid monomers linked by amide bonds and are distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered as peptides. Peptides act by binding to specific cell surface receptors and mimics like receptor ligands and help in treatment of diseases by acting on the cell membrane. The peptide therapeutics market is currently a booming one due to increase in cancer patient population to drive the growth of new peptides. Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in peptides innovative market. The CMOs which provide end-to-end service to the biotech pharmaceutical companies are growing due to shift in focus of pharma companies to explore better opportunities in the peptides market. Peptides initially had applications only in diagnostics and hormonal therapy; however with enhancement in technology, peptides are now being widely applied for therapeutic applications of cancer and metabolic diseases.

Browse Report with Complete TOC - http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

The peptide therapeutics market by application has been segmented as cancer, metabolic, CVD, respiratory, GIT, anti-infective, dermatology, CNS, renal and others. The cancer segment accounted for largest share of the peptide therapy market in 2015. This is because peptides have evolved as potential therapeutic agents for the treatment of cancer. Rising mortality due to cancer has led to an increase in focus for the development of new drugs and products to combat the situation. This is due to rapid rise in deaths caused by cancer, technological advancements and extensive R&D activities.

By route of administration market is categorized into parenteral, oral and others. The parenteral segment accounted for major share of the global peptide therapeutics market in 2015. This is due to wider availability of peptide drugs for parenteral route of administration as compared to other routes. However, peptides are destroyed by proteolytic enzymes and are easily and quickly accessible for orally administered drugs. Hence, the oral segment is expected to grow with the rapid increase in CAGR during the forecast period.

The innovative peptides dominates the peptide therapeutics market, by types and was accounted for key share of the global peptide therapeutics market in 2015. This is due to extensive R&D activities adopted by market players. Moreover, the innovative segment is anticipated to expand at a fast growth rate during the forecast period. This is due to the factor that a number of peptide drugs are in the pipeline (phase III) is likely for the innovative segment to experience outstanding growth rate by 2024.

Liquid phase, solid phase and hybrid phase are included into the market by technology. The liquid phase peptide synthesis segment accounted for key share of the global peptide therapeutics market in 2015. The liquid phase segment has been an ideal choice since it provides the maximum purity after synthesis of peptides. The hybrid phase segment is anticipated to expand at a high CAGR during the forecast period. This is due to the fact that companies are leveraging the benefits of this segment as this is both (solid and liquid) the technologies together that bring cost-effectiveness and economies of scale for peptides.

By type of molecule market is categorized into vasopressin, somatostatin, calcitonin, immunopeptide, natriuretic and others. The immunopeptide segment accounted for major share of the global peptide therapeutics market in 2015. This is due use of immunopeptide for the treatment of disease like cancer and tumors. As treatment of these diseases are critical, more investment is being made by the major players in research and development of different therapies for the treatment of diseases, which is further leading the investments in immune therapy. Hence, the immunopeptide segment is anticipated to expand at a fast growth rate during the forecast period.
The API peptide therapeutics market by type has been segmented into in-house and CMO. Companies, strong in infrastructure and requires large scale production, used to produce API in house which accounted the major share of the global peptide therapeutics market in 2015. Moreover, CMO is anticipated to expand at a high CAGR during the forecast period. This is due to API manufacturers now prefer to outsource peptides manufacturing to the contract manufacturing organizations (CMOs) as they provide end-to-end API peptides manufacturing and also have expertise and the high-end technology for various types of peptides.

Major players operating in the global peptide therapeutics market includes Sanofi, Teva Pharmaceutical Industries Ltd., Novo Nordisk, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Pfizer, Inc. and others.

Inquire for a Sample Copy of Report - http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.